With A 8.8% Return On Equity, Is Solara Active Pharma Sciences Limited (NSE:SOLARA) A Quality Stock?

In This Article:

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Solara Active Pharma Sciences Limited (NSE:SOLARA), by way of a worked example.

Our data shows Solara Active Pharma Sciences has a return on equity of 8.8% for the last year. One way to conceptualize this, is that for each ₹1 of shareholders' equity it has, the company made ₹0.088 in profit.

Check out our latest analysis for Solara Active Pharma Sciences

How Do You Calculate ROE?

The formula for return on equity is:

Return on Equity = Net Profit ÷ Shareholders' Equity

Or for Solara Active Pharma Sciences:

8.8% = ₹845m ÷ ₹9.6b (Based on the trailing twelve months to June 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. The easiest way to calculate shareholders' equity is to subtract the company's total liabilities from the total assets.

What Does Return On Equity Mean?

Return on Equity measures a company's profitability against the profit it has kept for the business (plus any capital injections). The 'return' is the profit over the last twelve months. The higher the ROE, the more profit the company is making. So, as a general rule, a high ROE is a good thing. That means it can be interesting to compare the ROE of different companies.

Does Solara Active Pharma Sciences Have A Good ROE?

Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Solara Active Pharma Sciences has a lower ROE than the average (13%) in the Pharmaceuticals industry.

NSEI:SOLARA Past Revenue and Net Income, September 24th 2019
NSEI:SOLARA Past Revenue and Net Income, September 24th 2019

Unfortunately, that's sub-optimal. We prefer it when the ROE of a company is above the industry average, but it's not the be-all and end-all if it is lower. Still, shareholders might want to check if insiders have been selling.

How Does Debt Impact ROE?

Virtually all companies need money to invest in the business, to grow profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the use of debt will improve the returns, but will not change the equity. That will make the ROE look better than if no debt was used.